Sanctuary Advisors LLC purchased a new position in shares of Organon & Co. (NYSE:OGN - Free Report) in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund purchased 268,590 shares of the company's stock, valued at approximately $5,560,000. Sanctuary Advisors LLC owned 0.10% of Organon & Co. at the end of the most recent reporting period.
Other institutional investors and hedge funds have also modified their holdings of the company. Vanguard Group Inc. grew its holdings in Organon & Co. by 0.6% during the 1st quarter. Vanguard Group Inc. now owns 30,789,850 shares of the company's stock worth $578,849,000 after acquiring an additional 192,613 shares during the period. LSV Asset Management boosted its position in shares of Organon & Co. by 47.3% in the 2nd quarter. LSV Asset Management now owns 6,610,768 shares of the company's stock worth $136,843,000 after purchasing an additional 2,121,940 shares during the last quarter. Nordea Investment Management AB grew its stake in shares of Organon & Co. by 26.9% during the first quarter. Nordea Investment Management AB now owns 3,970,328 shares of the company's stock worth $74,563,000 after purchasing an additional 841,518 shares during the period. AQR Capital Management LLC grew its stake in shares of Organon & Co. by 39.8% during the second quarter. AQR Capital Management LLC now owns 3,473,655 shares of the company's stock worth $71,905,000 after purchasing an additional 988,336 shares during the period. Finally, Deprince Race & Zollo Inc. increased its holdings in Organon & Co. by 6.8% in the second quarter. Deprince Race & Zollo Inc. now owns 3,421,703 shares of the company's stock valued at $70,829,000 after purchasing an additional 216,907 shares during the last quarter. 77.43% of the stock is owned by institutional investors.
NYSE OGN opened at $18.29 on Friday. The firm's 50 day moving average is $20.60 and its 200-day moving average is $20.14. The company has a quick ratio of 1.17, a current ratio of 1.64 and a debt-to-equity ratio of 60.05. The company has a market capitalization of $4.70 billion, a PE ratio of 4.47, a price-to-earnings-growth ratio of 0.84 and a beta of 0.84. Organon & Co. has a 12-month low of $10.84 and a 12-month high of $23.10.
Organon & Co. (NYSE:OGN - Get Free Report) last issued its earnings results on Tuesday, August 6th. The company reported $1.12 EPS for the quarter, topping the consensus estimate of $1.08 by $0.04. Organon & Co. had a negative return on equity of 840.29% and a net margin of 15.76%. The company had revenue of $1.61 billion during the quarter, compared to the consensus estimate of $1.61 billion. During the same period in the previous year, the company posted $1.31 EPS. The firm's revenue for the quarter was down .1% compared to the same quarter last year. Equities research analysts anticipate that Organon & Co. will post 4.14 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which was paid on Thursday, September 12th. Shareholders of record on Friday, August 16th were issued a $0.28 dividend. The ex-dividend date was Friday, August 16th. This represents a $1.12 annualized dividend and a dividend yield of 6.12%. Organon & Co.'s dividend payout ratio is currently 27.38%.
A number of equities analysts have issued reports on the company. Evercore ISI upgraded Organon & Co. to a "strong-buy" rating in a report on Wednesday, September 18th. JPMorgan Chase & Co. lowered shares of Organon & Co. from a "neutral" rating to an "underweight" rating and lifted their price objective for the stock from $18.00 to $20.00 in a research note on Friday, September 6th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, one has issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Organon & Co. presently has a consensus rating of "Hold" and an average target price of $21.00.
Read Our Latest Research Report on OGN
Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Organon & Co., you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Organon & Co. wasn't on the list.
While Organon & Co. currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.